Minimally invasive surgery linked to lower major complication risk, reduced length of stay, decreased transfusion rate.

Cytoreductive nephrectomy merits further consideration in appropriately risk-stratified, surgically fit patients with mRCC.

Deferred cytoreductive nephrectomy is associated with better survival compared with upfront surgery, including among fit patients receiving immunotherapy. Deferred cytoreductive nephrectomy (CN) may ...

Total tumor burden reductions of 10% or more achieved with presurgical systemic therapy significantly decrease mortality risk following cytoreductive nephrectomy. Findings from separate studies ...

PN and RFA offer similar survival for cT1a RCC tumors ≤2 cm, but PN is superior for larger tumors. RFA may be considered for elderly patients with comorbidities, especially for tumors ≤2 cm. PN ...